Heron

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

Retrieved on: 
水曜日, 6月 12, 2024
Acquisition, Dupilumab, Chairperson, Patient, AstraZeneca, Atopic dermatitis, Ardea, RNA, Connect, SAN, Therapy, Mergers and acquisitions, Publication, Gout, Regulus Therapeutics, University, Heron, Pharming, DRS, Asthma, FDA, Quart, General counsel, Law, Inflammation, Food, Food and Drug Administration, MEK, Bayer, Element, Biotechnology, Abstract, Cancer, CINV, Pharmaceutical industry

Dr. Xanthopoulos, currently the lead independent member of the Board since 2022, has been appointed Chair of the Board.

Key Points: 
  • Dr. Xanthopoulos, currently the lead independent member of the Board since 2022, has been appointed Chair of the Board.
  • “On behalf of the board and the Connect team I would like to thank Drs.
  • We are grateful for their contributions and unwavering commitment to the Connect mission by building an outstanding organization with Phase 3-ready programs and a robust pipeline,” said Kleanthis G. Xanthopoulos, Ph.D., Chair of the Board of Directors of Connect.
  • "As Connect evolved to focus on advancing rademikibart, Bill and I look forward to supporting Barry and David as Connect enters an exciting new phase."

Heron Finance Hires Khang Nguyen as Chief Credit Officer and Michael Jen as Head of Compliance

Retrieved on: 
水曜日, 5月 29, 2024
Technology, Finance, Fintech, Professional Services, Blockchain, Networks, Data Analytics, Cryptocurrency, Data Management, Princeton University, Investment, Silicon, University, Heron, MBA, Research, Morgan Stanley, Wells Fargo, BlackRock, Risk management, University of Phoenix

Heron Finance , an SEC-registered investment advisor (“RIA”) focused on private credit, today announced it has hired Khang Nguyen as chief credit officer and Michael Jen as head of compliance.

Key Points: 
  • Heron Finance , an SEC-registered investment advisor (“RIA”) focused on private credit, today announced it has hired Khang Nguyen as chief credit officer and Michael Jen as head of compliance.
  • In the role of chief credit officer at Heron Finance, Khang Nguyen will oversee all aspects of credit strategy, research, underwriting, and portfolio management.
  • As head of compliance, Michael Jen will focus on investment advisory compliance oversight, implementation, and strategic initiatives.
  • “Heron Finance uses a more transparent and efficient technology platform to provide wider access to private credit investments than ever before,” said Mike Sall, co-founder and CEO of Heron Finance.

Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates

Retrieved on: 
火曜日, 5月 7, 2024
PFS, FDA, Elective surgery, Partnership, VAN, Foot, Cross-link, Physician, Heron, Ankle, Adjustment, Human, Therapy, SAN, Pharmaceutical industry

Launched partnership with CrossLink Life Sciences, LLC to expand ZYNRELEF® promotional efforts in the first quarter of 2024.

Key Points: 
  • Launched partnership with CrossLink Life Sciences, LLC to expand ZYNRELEF® promotional efforts in the first quarter of 2024.
  • Gross Margin improved to 76% for the quarter, up from 43% for the same period last year.
  • Heron to host its first ever Investor Day event on Wednesday, May 15, 2024 in New York, New York.
  • SAN DIEGO, May 7, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2024 and highlighted recent corporate updates.

New open software code for the home gateway redefines broadband experience

Retrieved on: 
木曜日, 4月 25, 2024
Data Management, Security, Technology, Software, Networks, Internet, ISP, Prpl Foundation, ARPU, Broadband Forum, Internet service provider, CPE, Customer, Heron

Value-added services like cybersecurity, remote working, and gaming experience controls are key for broadband providers to transition to providing services-led broadband with greater user experience and satisfaction.

Key Points: 
  • Value-added services like cybersecurity, remote working, and gaming experience controls are key for broadband providers to transition to providing services-led broadband with greater user experience and satisfaction.
  • The software lifecycle of these applications can also be managed by the ISP, streamlining the process of introducing new services.
  • Broadband Forum CEO Craig Thomas said: “This really is a holy grail of sorts for an app-enabled services gateway and for other CPE.
  • We’ve worked closely with prpl Foundation to bring this innovation to reality, and the Open Broadband USP Agent is a key part of that.

Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

Retrieved on: 
水曜日, 4月 24, 2024
Heron, Webcast, SAN

SAN DIEGO, April 24, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, May 7, 2024, at 8:30 a.m.

Key Points: 
  • SAN DIEGO, April 24, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, May 7, 2024, at 8:30 a.m.
  • ET to report first quarter 2024 financial results and discuss recent business highlights.
  • The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com .
  • An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.

Mill Creek's Frontier Dermatology Is First in Washington to Offer Nonsurgical Treatment for Common Skin Cancer Using Image-Guided Superficial Radiation Therapy

Retrieved on: 
水曜日, 4月 17, 2024
Pain, Patient, Bleeding, Carcinoma, FAAD, Skin, Oncology, Therapy, SRT, Dermatology, Heron, Medical imaging

This is the first medical practice in the state to offer this GentleCure™ treatment experience.

Key Points: 
  • This is the first medical practice in the state to offer this GentleCure™ treatment experience.
  • Dieter Schmidt, M.D., FAAD, FACMS, of Frontier Dermatology, noted, "More than 68,000 Washingtonians are expected to be diagnosed with nonmelanoma skin cancer this year alone.
  • We call it the GentleCure experience, and we are proud to be the first in Washington to offer it."
  • "Patients everywhere should have the choice of curing their nonmelanoma skin cancer without surgery."

Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City

Retrieved on: 
木曜日, 4月 11, 2024
Heron, Therapy, Acute care, Webcast, SAN, Oncology

SAN DIEGO, April 11, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on Wednesday, May 15, 2024 in New York City, beginning at 9:30 am ET.

Key Points: 
  • SAN DIEGO, April 11, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on Wednesday, May 15, 2024 in New York City, beginning at 9:30 am ET.
  • The presentations will also include updates on several ongoing initiatives in the Acute Care franchise to expand reach and adoption.
  • The event will include a live webcast which will be archived and available for replay after the event.
  • Please visit the "Investors" section of the Company website at Investor Resources - Heron Therapeutics (herontx.com) to register for the webcast and for additional information on the event.

Sabanci University Will Host the "Sakura Festival" on the 100th Anniversary of the Establishment of Diplomatic Relations Between Turkey and Japan

Retrieved on: 
水曜日, 3月 13, 2024
Energy, Other Communications, Manufacturing, Technology, University, Education, Communications, Other Automotive, Other Entertainment, Electronic Games, Other Manufacturing, Telecommunications, Automotive, Entertainment, Other Energy, Heron, Student, Boy, Future, Multimedia, Flower

What is the “Make a Promise for the Future” Scholarship Fund?

Key Points: 
  • What is the “Make a Promise for the Future” Scholarship Fund?
  • It takes its inspiration from the promises of young people to solve problems for a stronger future and a better world.
  • All proceeds from the "Sakura Festival Gala Event" ticket sales will be transferred to Sabancı University's "Make a Promise for the Future" Scholarship Program.
  • Those who wish to buy tickets to attend the Sakura Festival Gala Event , can click on the link.

Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
木曜日, 3月 28, 2024
SAN, Conference, Therapy, Heron

SAN DIEGO, March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024, at 11:00 AM ET at the 23rd Annual Needham Virtual Healthcare Conference.

Key Points: 
  • SAN DIEGO, March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024, at 11:00 AM ET at the 23rd Annual Needham Virtual Healthcare Conference.
  • The conference is being held in a virtual format, April 8-11, 2024.
  • A live webcast of the fireside chat will be available on the Company's website at www.herontx.com in the Investor Resources section.

Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates

Retrieved on: 
火曜日, 3月 12, 2024
Webcast, Bupivacaine, Granisetron, Aprepitant, Meloxicam, Heron

ZYNRELEF Net Product Sales: Net Product Sales of ZYNRELEF (bupivacaine and meloxicam) extended-release solution for the three and twelve months ended December 31, 2023 were $5.6 million and $17.7 million, respectively, which increased from $3.9 million and $10.2 million, respectively, for the same periods in 2022.

Key Points: 
  • ZYNRELEF Net Product Sales: Net Product Sales of ZYNRELEF (bupivacaine and meloxicam) extended-release solution for the three and twelve months ended December 31, 2023 were $5.6 million and $17.7 million, respectively, which increased from $3.9 million and $10.2 million, respectively, for the same periods in 2022.
  • APONVIE® Net Product Sales: Net Product Sales of APONVIE for the three and twelve months ended December 31, 2023 were $0.5 million and $1.4 million, respectively, with no sales in the comparable prior year periods.
  • CINVANTI® Net Product Sales: Net Product Sales of CINVANTI (aprepitant) injectable emulsion for the three and twelve months ended December 31, 2023 were $24.3 million and $94.9 million, respectively, which increased from $23.1 million and $87.3 million, respectively, for the same periods in 2022.
  • SUSTOL® Net Product Sales: Net Product Sales of SUSTOL (granisetron) extended-release injection for the three and twelve months ended December 31, 2023 were $3.8 million and $13.0 million, respectively, which increased from $3.0 million and $10.2 million, respectively, for the same periods in 2022.